Novartis files for Gleevec to treat four other cancers

04/10/2006 | Wall Street Journal, The

Novartis has applied in the U.S. and European Union to have its Gleevec, which is currently approved for treating types of leukemia and stomach cancers, also approved for use in fighting four other types of cancer. The filings are an indication of a movement under way in the drug industry in which the emphasis of cancer treatment is on genetic mutations now believed to be the cause of cancers, instead of specific body parts, The Wall Street Journal asserts.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID